CD8A and rheumatoid arthritis: 2014; Cheng et al. 2020). These components may be involved in the therapeutic effect in RA. WTD decreases inflammatory factors, including interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-α), modulates the proportions of CD4+/CD8+ in peripheral blood, and alleviates the pain of joints in patients with RA (He et al. 2018; Zhu et al. 2018).